Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM. Blaney SM, et al. Among authors: sato jk. Clin Cancer Res. 1998 Feb;4(2):357-60. Clin Cancer Res. 1998. PMID: 9516923 Clinical Trial.
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH. Dinndorf PA, et al. Among authors: sato jk. J Clin Oncol. 1997 Aug;15(8):2780-5. doi: 10.1200/JCO.1997.15.8.2780. J Clin Oncol. 1997. PMID: 9256119 Clinical Trial.
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH. Cairo MS, et al. Among authors: sato jk. J Pediatr Hematol Oncol. 2001 Jan;23(1):30-8. doi: 10.1097/00043426-200101000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11196267 Clinical Trial.
Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G. Meany HJ, et al. Among authors: sato jk. J Immunother. 2015 Sep;38(7):299-305. doi: 10.1097/CJI.0000000000000088. J Immunother. 2015. PMID: 26261894 Free PMC article. Clinical Trial.
31 results